The European Commission invests in the development of innovative products against respiratory viruses

The European Commission, with the support of the European Investment Bank, will provide €20 million in the development of nasal sprays designed to protect against respiratory viruses. For this purpose, the Commission through its Health Emergency Preparedness and Response Authority (HERA), has signed an investment agreement with the Dutch biotech company Leyden Labs. 

The nasal spray delivers antibodies directly into the nasal cavity, stopping infections at the point of entry, and potentially preventing onward transmission. By targeting commonalities among virus families, rather than one variant in particular, this innovative approach provides broad protection against various existing and new viruses. The technology provides a universal solution to respiratory viruses, regardless of an individual's immune history – for example, people who do not sufficiently respond to a vaccine, or don't get vaccinated.

Hadja Lahbib, Commissioner for Equality, Preparedness and Crisis Management, said: “Respiratory viruses are common and affect us all, especially the most medically vulnerable. Today's agreement reaffirms our commitment to invest in innovation to strengthen preparedness and protection against respiratory viruses. HERA Invest is a prime example of Europe at the forefront of medical advancements in response to serious threats to health.”